2021 Q2 Form 10-Q Financial Statement
#000156459021044463 Filed on August 16, 2021
Income Statement
| Concept | 2021 Q2 | 2020 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | -100.0% | |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $2.224M | $670.0K |
| YoY Change | 192.63% | -84.94% |
| % of Gross Profit | ||
| Research & Development | $3.523M | $3.141M |
| YoY Change | -89.02% | -74.74% |
| % of Gross Profit | ||
| Depreciation & Amortization | $17.00K | $57.00K |
| YoY Change | -15.0% | -73.61% |
| % of Gross Profit | ||
| Operating Expenses | $5.747M | $3.141M |
| YoY Change | -82.1% | -81.39% |
| Operating Profit | -$5.747M | |
| YoY Change | ||
| Interest Expense | ||
| YoY Change | ||
| % of Operating Profit | ||
| Other Income/Expense, Net | -$65.00K | -$23.00K |
| YoY Change | 550.0% | -89.2% |
| Pretax Income | -$5.812M | -$2.050M |
| YoY Change | -83.28% | -88.0% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$5.812M | -$2.050M |
| YoY Change | -83.28% | 73.0% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | -$0.43 | |
| Diluted Earnings Per Share | -$0.43 | -$967.0K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 13.60M | 23.90M |
| Diluted Shares Outstanding | 13.60M |
Balance Sheet
| Concept | 2021 Q2 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $50.80M | $4.119M |
| YoY Change | 83.38% | -94.86% |
| Cash & Equivalents | $50.80M | $4.119M |
| Short-Term Investments | $0.00 | |
| Other Short-Term Assets | $1.086M | $300.0K |
| YoY Change | 171.5% | -81.25% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $51.88M | $14.51M |
| YoY Change | 84.63% | -82.24% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $70.00K | $694.0K |
| YoY Change | -30.0% | -81.8% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $936.0K | |
| YoY Change | ||
| Total Long-Term Assets | $1.006M | $4.123M |
| YoY Change | 403.0% | -68.31% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $51.88M | $14.51M |
| Total Long-Term Assets | $1.006M | $4.123M |
| Total Assets | $52.89M | $18.63M |
| YoY Change | 86.88% | -80.33% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $985.0K | $1.627M |
| YoY Change | -62.12% | -41.89% |
| Accrued Expenses | $1.993M | $6.030M |
| YoY Change | 130.14% | -46.16% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $5.000M | |
| YoY Change | 127.27% | |
| Total Short-Term Liabilities | $2.978M | $12.64M |
| YoY Change | -12.41% | -21.99% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | -100.0% | |
| Other Long-Term Liabilities | $3.900M | |
| YoY Change | -59.38% | |
| Total Long-Term Liabilities | $0.00 | $3.900M |
| YoY Change | -88.43% | |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $2.978M | $12.64M |
| Total Long-Term Liabilities | $0.00 | $3.900M |
| Total Liabilities | $2.978M | $16.55M |
| YoY Change | -12.41% | -66.83% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$62.10M | -$289.7M |
| YoY Change | 48.56% | 24.34% |
| Common Stock | $291.8M | |
| YoY Change | 5.02% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $49.91M | -$6.772M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $52.89M | $18.60M |
| YoY Change | 86.88% | -80.36% |
Cashflow Statement
| Concept | 2021 Q2 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$5.812M | -$2.050M |
| YoY Change | -83.28% | 73.0% |
| Depreciation, Depletion And Amortization | $17.00K | $57.00K |
| YoY Change | -15.0% | -73.61% |
| Cash From Operating Activities | -$3.938M | -$2.865M |
| YoY Change | -1.8% | -83.8% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | ||
| YoY Change | ||
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | |
| YoY Change | -100.0% | |
| Cash From Investing Activities | $0.00 | $12.72M |
| YoY Change | -100.0% | 108.66% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $10.00K | |
| YoY Change | -95.97% | |
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -32.00K | 45.00K |
| YoY Change | -100.13% | -97.46% |
| NET CHANGE | ||
| Cash From Operating Activities | -3.938M | -2.865M |
| Cash From Investing Activities | 0.000 | 12.72M |
| Cash From Financing Activities | -32.00K | 45.00K |
| Net Change In Cash | -3.970M | -2.820M |
| YoY Change | -116.8% | -71.27% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$3.938M | -$2.865M |
| Capital Expenditures | ||
| Free Cash Flow | ||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y11M8D | |
| CY2021Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y10M2D | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y10M20D | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y11M19D | ||
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y10M6D | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y8M15D | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P8Y9M | ||
| CY2020Q2 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
32057000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
45000 | |
| CY2020Q2 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
10515000 | |
| CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
43000 | |
| CY2020Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
24016000 | |
| CY2020Q2 | fbrx |
Stock Issued During Period Value Reverse Merger
StockIssuedDuringPeriodValueReverseMerger
|
31809000 | |
| CY2020Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
47000 | |
| CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
24000 | |
| CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1244000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-6772000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
58980000 | |
| fbrx |
Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
|
10515000 | ||
| us-gaap |
Stock Issued1
StockIssued1
|
31809000 | ||
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
58765000 | |
| CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
27749000 | |
| CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
24878000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
27000 | |
| CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
495000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4804000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
54698000 | |
| CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5812000 | |
| CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
49909000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-10616000 | ||
| fbrx |
Non Cash Research And Development In Process Acquired
NonCashResearchAndDevelopmentInProcessAcquired
|
30885000 | ||
| us-gaap |
Depreciation
Depreciation
|
27000 | ||
| us-gaap |
Depreciation
Depreciation
|
27000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1503000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
26000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-399000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1385000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-255000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
959000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
974000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-3352000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-7968000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6881000 | ||
| fbrx |
Cash And Restricted Cash Acquired In Reverse Merger
CashAndRestrictedCashAcquiredInReverseMerger
|
3583000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
3583000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
24016000 | ||
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
44000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
42000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
92000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-2000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
24108000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-7970000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
20810000 | ||
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
6939000 | |
| CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
50795000 | |
| CY2021Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-62100000 | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-8000000.0 | ||
| CY2021Q2 | fbrx |
Transfers Between Fair Value Hierarchy Levels
TransfersBetweenFairValueHierarchyLevels
|
0 | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. Significant management estimates that affect the reported amounts of assets and liabilities include useful lives of property and equipment, stock-based compensation, accruals for clinical trials and drug manufacturing and deferred tax assets. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. </span></p> | ||
| CY2020Q2 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
32100000 | |
| us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
0 | ||
| us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
0 | ||
| CY2020Q4 | fbrx |
Accrued Manufacturing And Clinical Expenses
AccruedManufacturingAndClinicalExpenses
|
237000 | |
| CY2021Q2 | fbrx |
Accrued Compensation
AccruedCompensation
|
593000 | |
| CY2020Q4 | fbrx |
Accrued Compensation
AccruedCompensation
|
646000 | |
| CY2021Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
63000 | |
| CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
50000 | |
| CY2021Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1993000 | |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1019000 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2428454 | ||
| CY2021Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2428454 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3578890 | ||
| CY2020Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3578890 | |
| CY2021Q2 | fbrx |
Prepaid Manufacturing And Clinical Expenses
PrepaidManufacturingAndClinicalExpenses
|
680000 | |
| CY2020Q4 | fbrx |
Prepaid Manufacturing And Clinical Expenses
PrepaidManufacturingAndClinicalExpenses
|
488000 | |
| CY2021Q2 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
217000 | |
| CY2020Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
395000 | |
| CY2021Q2 | fbrx |
Prepaid License
PrepaidLicense
|
50000 | |
| CY2020Q4 | fbrx |
Prepaid License
PrepaidLicense
|
100000 | |
| CY2020Q4 | us-gaap |
Prepaid Taxes
PrepaidTaxes
|
74000 | |
| CY2021Q2 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
139000 | |
| CY2020Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
76000 | |
| CY2021Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1086000 | |
| CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1133000 | |
| CY2021Q2 | fbrx |
Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
|
763000 | |
| CY2020Q4 | fbrx |
Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
|
861000 | |
| CY2021Q2 | fbrx |
Deposits For Manufacturing Components
DepositsForManufacturingComponents
|
116000 | |
| CY2020Q4 | fbrx |
Deposits For Manufacturing Components
DepositsForManufacturingComponents
|
82000 | |
| CY2021Q2 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
44000 | |
| CY2020Q4 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
289000 | |
| CY2021Q2 | us-gaap |
Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
|
13000 | |
| CY2020Q4 | us-gaap |
Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
|
12000 | |
| CY2021Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
936000 | |
| CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1244000 | |
| CY2021Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
118000 | |
| CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
86000 | |
| CY2021Q2 | fbrx |
Accrued Manufacturing And Clinical Expenses
AccruedManufacturingAndClinicalExpenses
|
1219000 | |
| CY2021Q2 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
250000 | |
| CY2021Q2 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P6M | |
| CY2021Q2 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
6000 | |
| fbrx |
Rent Credit Due To Refund For Operating Expense Adjustments
RentCreditDueToRefundForOperatingExpenseAdjustments
|
9000 | ||
| CY2020Q2 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
8000 | |
| us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
14000 | ||
| CY2021Q2 | us-gaap |
Contractual Obligation
ContractualObligation
|
100000 | |
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
23.40 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
23.29 | ||
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
10.08 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
8.17 | ||
| CY2021Q2 | fbrx |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
|
38.14 | |
| CY2020Q2 | fbrx |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
|
16.53 | |
| fbrx |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
|
37.89 | ||
| fbrx |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
|
13.39 | ||
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0103 | |
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0040 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0096 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0059 | ||
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | |
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | ||
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.697 | |
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.700 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.698 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.700 | ||
| CY2020Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
24000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1503000 | ||
| CY2021Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1008000 | |
| CY2021Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
13300000 | |
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y14D | ||
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1123496 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
11.72 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
27800000 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
401500 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
37.89 | ||
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
9594 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
4.40 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
282000 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
119498 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
21.46 | ||
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1395904 | |
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
18.46 | |
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
23174000 | |
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
164956 | |
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
14.44 | |
| CY2021Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
3177000 | |
| fbrx |
Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value Of Stock Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueOfStockPrice
|
33.62 |
